Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  crizotinib
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
Crizotinib in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL0912, NCI-2011-01937, CDR0000647587, COG-ADVL0912, NCT01182896, P10666, NCT00939770
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1306, NCI-2013-00737, NCT01822496
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BRE12-158, NCI-2015-00307, NCT02101385
Pemetrexed Disodium with or without Crizotinib in Treating Patients with Stage IV Non-small Cell Lung Cancer That Has Progressed after Treatment with Crizotinib Alone
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1300, NCI-2014-00685, NCT02134912
Crizotinib following Surgery or Radiation Therapy in Treating Patients with High-Risk Uveal Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-063, NCI-2014-01895, NCI-2015-00689, NCT02223819
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A8081001, NCI-2009-01775, PROFILE 1001, NCT00585195
Crizotinib, Pazopanib Hydrochloride, and Pemetrexed Disodium in Treating Patients with Recurrent or Refractory Cancer
Phase: Phase I
Type: Treatment
Age: not specified
Trial IDs: 2011-1142, NCI-2012-00324, NCT01548144
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A8081012, NCI-2012-01184, NCT01576406
Crizotinib and Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 21 years
Trial IDs: ADVL1212, NCI-2012-01968, CDR0000734059, COG-ADVL1212, NCT01606878
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Dasatinib and Crizotinib in Treating Patients with Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 16 and over
Trial IDs: 2012-0721, NCI-2013-00071, NCT01744652
Ipilimumab and Erlotinib Hydrochloride or Crizotinib in Treating Patients with Stage IV Non-small Cell Lung Cancer or Stage II-III Non-small Cell Lung Cancer That Cannot Be Treated with Standard Techniques
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI66705/IRB# 66705, NCI-2013-02290, CA184-350, HCI66705, IRB# 66705, NCT01998126
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
Crizotinib and Enzalutamide in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-230, NCI-2014-02361, NCT02207504
Start Over